All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2023; the latest 2024-04-30.
From the record
NewGenIvf Group Limited's filings since 2023 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-04-30) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+3.5% a year over 5 filed years; profitable in 3 of 5.
From the record
NewGenIvf Group Limited's 5 filed years say what it did: revenue went from $4 million in fiscal 2021 to $5 million in fiscal 2025, up 3.5% a year; it rose in 2 of 4 years; the deepest fall was 20% from fiscal 2022 to fiscal 2025; net income was positive in 3 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 383.1% a year. 0% of cash flow returned. Insiders: 0 sales, 4 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, NewGenIvf Group Limited's diluted share count grew about 383.1% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 0 sales and 4 purchases of their own stock on the open market in the year to 2026-10-06, buying about $4 million (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 38%: 38¢ of profit per shareholder dollar. Leverage 21%: owes 21¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, NewGenIvf Group Limited earned about 38 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 3 cents per dollar of everything the company owns. Leverage: it owed about 21 cents per dollar of assets, and net share issuance: its share count grew 2731009.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 43% of 10 in its family; net margin 209%.
From the record
NewGenIvf Group Limited's standing among 10 graded names in its industry family: revenue of $5 million in fiscal 2025 ranks in the bottom 28% by size; a net margin of 209% ranks in the top 5%; revenue growth of -7.4% a year over the last 3 filed years ranks in the bottom 5% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 0.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: NewGenIvf Group Limited's leadership is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the bottom 6% of 10 in its family; it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-23 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 29% of 10 in its family for room to expand.
From the record
NewGenIvf Group Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $759 thousand against no long-term debt tagged leaves 2.3% of its assets as net cash, top 45% of its family; cash from operations less capital spending is -234% of revenue (bottom 25%); a gross margin of 20.2% (bottom 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 35% of 10 in its family for growth drivers.
From the record
NewGenIvf Group Limited's growth drivers, from the filed years to fiscal 2025: revenue grew -7.4% a year over the last three filed years against 3.5% over all 5, slowing (bottom 15% of its family); the newest year grew -13% (bottom 15%); capital spending grew 12.6% a year (top 25%) (its annual reports). NewGenIvf Group Limited reported 2 product lines in fiscal 2025: IVF Treatment Service at $4 million (83%), Fertility Referral Services at $821 thousand (17%); 0 of 1 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 28% of 10 in its family for expectations against reality.
From the record
NewGenIvf Group Limited's newest year against its own record: revenue of $5 million in fiscal 2025 came in 9% below the $5 million its prior three years' pace pointed to (bottom 45% of its family); net income of $10 million against a prior three-year average of $21 thousand (top 5%); a net margin of more than its whole revenue against 0.2% before (top 25%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made